Epidemiological Analysis of the SARS-Cov2 Pandemic in the Mexican Population; midway evaluation, characteristics, comorbidity and risk.
Keywords:
COVID – 19, SARS-Cov2, Epidemiology, Mexico, InfectionAbstract
Given the relevance of documenting the SARS-COv2 pandemic in Mexico, a first evaluation and analysis exercise considered halfway is done, which confirms a spectrum of characteristics with the world reference that preceded it, but emphasizes in conditions that are of the most importance for the country, such as the wide and known risk that the population has with respect to chronic metabolic and cardiovascular diseases; as well as a collective environment on which the disease would be arriving, with a population in transit of a political regime, the proposed structural modification actions, as well as the known deterioration of public institutions, including the national health system. The results of the epidemiological analysis are presented, in which the increased risk in men stands out, and according to a gradient of age, growth, which corresponds to greater conditions of severity and death. Independently diabetes mellitus, hypertension, chronic kidney disease and immunosuppression, as well as management indicators in the face of severity, establish the comprehensive need for broader approaches, as well as the incursion into evaluations linked to the collective environment of the Mexican population.
Downloads
References
1. WHO | Pneumonia of unknown cause – China. WHO. 2020; https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/ (Acceso 15/06/2020)
2. Bagcchi S. Mysterious pneumonia in China. Lancet Infect Dis. 2020 Feb 1;20(2):173.
3. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Vol. 63, Science China Life Sciences. Science in China Press; 2020. p. 457–60.
4. Cortés ME. Coronavirus como amenaza a la salud pública. Rev Med Chil [Internet]. 2020 Jan [cited 2020 Jun 15];148(1):124–6. Available from: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000100124&lng=en&nrm=iso&tlng=en
5. Bassetti M, Vena A, Giacobbe DR. The novel Chinese coronavirus (2019-nCoV) infections: Challenges for fighting the storm. Vol. 50, European Journal of Clinical Investigation. Blackwell Publishing Ltd; 2020.
6. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054–62.
7. Zhang N, Wang L, Deng X, Liang R, Su M, He C, et al. Recent advances in the detection of respiratory virus infection in humans. Vol. 92, Journal of Medical Virology. John Wiley and Sons Inc.; 2020. p. 408–17.
8. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020 Mar 12;579(7798):265–9.
9. Zhou P, Yang X Lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar 12;579(7798):270–3.
10. Wu Y-C, Chen C-S, Chan Y-J. The outbreak of COVID-19: An overview. J Chinese Med Assoc [Internet]. 2020 [cited 2020 Jun 15];83:217–20. Available from: www.ejcma.org
11. Loades ME, Chatburn E, Higson-Sweeney N, Reynolds S, Shafran R, Brigden A, et al. Rapid Systematic Review: The Impact of Social Isolation and Loneliness on the Mental Health of Children and Adolescents in the Context of COVID-19. J Am Acad Child Adolesc Psychiatry [Internet]. 2020 Jun 3 [cited 2020 Jun 15]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/32504808
12. Crespo RM, Morales Crespo MM. Pandemia COVID-19, la nueva emergencia sanitaria de preocupación internacional: una revisión. Med Fam Semer. 2020 May;
13. Palacios Cruz M, Santos E, Velázquez Cervantes MA, León Juárez M. COVID-19, a worldwide public health emergency. Revista Clinica Espanola. Elsevier Doyma; 2020.
14. Khan Z, Karataş Y, Fahriye Ceylan A, Rahman H. COVID-19 and therapeutic drugs repurposing in hand: the need for collaborative efforts. Le Pharm Hosp Clin [Internet]. 2020 Jun [cited 2020 Jun 15]; Available from: https://linkinghub.elsevier.com/retrieve/pii/S2211104220300795
15. Chiappelli F. Volume 16(2) Editorial 2019-nCoV-Towards a 4 th generation vaccine. Bioinformation [Internet]. 2020 [cited 2020 Jun 15];16(2):139–44. Available from: www.bioinformation.net
16. Bhagavathula AS, Aldhaleei WA, Rovetta A, Rahmani J. Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials. Cureus [Internet]. 2020 May 28 [cited 2020 Jun 15];12(5):e8342. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32494546
17. Fernandes EG, Da J, Santos S, Keico H, Iii S. Outbreak investigation in cargo ship in times of COVID-19 crisis, Port of Santos, Brazil. 2020 [cited 2020 Jun 15]; Available from: http://doi.org/10.11606/s1518-8787.2020054002461
18. Rodriguez-Morales AJ, Gallego V, Escalera-Antezana JP, Méndez CA, Zambrano LI, Franco-Paredes C, et al. COVID-19 in Latin America: The implications of the first confirmed case in Brazil. Travel Medicine and Infectious Disease. Elsevier USA; 2020.
19. Amariles P, Granados J, Ceballos M, Montoya CJ. COVID-19 in Colombia endpoints. Are we different, like Europe? Res Soc Adm Pharm. 2020;
20. Skums P, Kirpich A, Baykal PI, Zelikovsky A, Chowell G. Global transmission network of SARS-CoV-2: from outbreak to pandemic. medRxiv. 2020;2020.03.22.20041145.
21. Gemelli NA. Management of COVID-19 Outbreak in Argentina: The Beginning. Disaster Med Public Health Prep. 2020;1.
22. Suárez V, Suarez Quezada M, Oros Ruiz S, Ronquillo De Jesús E. Epidemiología de COVID-19 en México: del 27 febrero al 30 de abril de 2020. Rev Clínica Española [Internet]. 2020 May [cited 2020 Jun 15]; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0014256520301442
23. Lai CC, Wang CY, Wang YH, Hsueh SC, Ko WC, Hsueh PR. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicrob Agents. 2020 Apr 1;55(4):105946.
24. Torrealba-Rodriguez O, Conde-Gutiérrez RA, Hernández-Javier AL. Modeling and prediction of COVID-19 in Mexico applying mathematical and computational models. Chaos, Solitons and Fractals. 2020 Sep 1;138.
25. COVID-19 Tablero México - CONACYT - CentroGeo - GeoInt - DataLab [Internet]. [cited 2020 Jun 15]. Available from: https://coronavirus.gob.mx/datos/
26. Chiappetta S, Sharma AM, Bottino V, Stier C. COVID-19 and the role of chronic inflammation in patients with obesity. Int J Obes. 2020 May 14;1–3.
27. Martínez-Anaya C, Ramos-Cervantes P, Vidaltamayo R. Coronavirus, diagnóstico y estrategias epidemiológicas contra COVID-19 en México. Educ Química. 2020 Apr 15;31(2):12.
28. Cordera R, Provencio E. Cambiar el rumbo: el desarrollo tras la pandemia [Internet]. 2020 [cited 2020 Jun 17]. Available from: http://www.nuevocursodedesarrollo.unam.mx/docs/GNCD_Cambiarelrumbo.pdf#page=103
29. Datos Abiertos - Dirección General de Epidemiología | Secretaría de Salud | Gobierno | gob.mx [Internet]. [cited 2020 Jun 15]. Available from: https://www.gob.mx/salud/documentos/datos-abiertos-152127
30. PROYECCIÓN PRELIMINAR DEL CORONAVIRUS (COVID-19) PARA MÉXICO [Internet]. [cited 2020 Jun 15]. Available from: https://www.researchgate.net/publication/340032649_PROYECCION_PRELIMINAR_DEL_CORONAVIRUS_COVID-19_PARA_MEXICO
31. Gabutti G, d’Anchera E, Sandri F, Savio M, Stefanati A. Coronavirus: Update Related to the Current Outbreak of COVID-19. Vol. 9, Infectious Diseases and Therapy. Adis; 2020.
32. Ekiz T, Pazarlı AC. Relationship between COVID-19 and obesity. Diabetes Metab Syndr Clin Res Rev. 2020 Sep 1;14(5):761–3.
33. Jain V, Yuan J-M. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. Int J Public Health [Internet]. 2020 May 25 [cited 2020 Jun 15];1. Available from: http://link.springer.com/10.1007/s00038-020-01390-7
34. Chen L, Yu J, He W, Chen L, Yuan G, Dong F, et al. Risk factors for death in 1859 subjects with COVID-19. [cited 2020 Jun 17]; Available from: https://doi.org/10.1038/s41375-020-0911-0
35. Agudelo-Botero M, Valdez-Ortiz R, Giraldo-Rodríguez L, González-Robledo MC, Mino-León D, Rosales-Herrera MF, et al. Overview of the burden of chronic kidney disease in Mexico: Secondary data analysis based on the Global Burden of Disease Study 2017. BMJ Open. 2020 Mar 25;10(3):e035285.
36. Wyper GMA, Assunção R, Cuschieri S, Devleeschauwer B, Fletcher E, Haagsma JA, et al. Population vulnerability to COVID-19 in Europe: a burden of disease analysis. Arch Public Heal [Internet]. 2020 Dec 29 [cited 2020 Jun 15];78(1):47. Available from: https://archpublichealth.biomedcentral.com/articles/10.1186/s13690-020-00433-y
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Escuela de Salud Pública y Ambiente. Facultad de Ciencias Médicas. Universidad Nacional de Córdoba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License which allows the work to be copied, distributed, exhibited and interpreted as long as it is not done for commercial purposes.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) after the publication process. (See The Effect of Open Access). (See The Effect of Open Access).
